{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"83"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"86"}],"units":"Participants"}],"description":"An AE was defined as any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a study drug, whether considered related to study drug or not. A summary of serious and all other non-serious AEs, regardless of causality, is located in the Reported Adverse Events module.\n\nA treatment-emergent adverse event (TEAE) is defined as an AE that had an onset date or a worsening in severity from baseline (pretreatment) on or after the date of first dose of study drug up to 30 days following study drug discontinuation (Safety Follow-up visit) or initiation of new anticancer therapy, whichever comes first.","groups":[{"description":"Zanubrutinib (160 mg) administered BID until disease progression, unacceptable toxicity or death, withdrawal of consent, lost to follow up, or study termination by sponsor, which comes first.","id":"OG000","title":"Zanubrutinib"}],"paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"Safety Analysis Set: All participants who received any dose of study drug.","reportingStatus":"POSTED","timeFrame":"From the initiation of study drug until 30 days after the last dose (Up to 3 years and 6 months)","title":"Number Of Participants Experiencing Treatment -Emergent Adverse Events (AEs)","type":"SECONDARY","unitOfMeasure":"Participants"}